THE EFFECT OF CARBOPLATIN CHEMOTHERAPY REGULATION ON HEARING FUNCTIONS IN PATIENTS OF NASOPHARYNGEAL CARCINOMA by Wahyuni, Ita et al.
International Journal of Nasopharyngeal Carcinoma (IJNPC) Vol. 01, No. 02, 2019 | 61-65 
 
International Journal of  
NASOPHARYNGEAL CARCINOMA 
 
 
Journal homepage: ijnpc.usu.ac.id 
 
 
Copyright © International Journal of Nasopharyngeal Carcinoma, Published by Talenta Publisher, ISSN: 2656-9027 e-ISSN: 2656-9035, DOI: 10.32734/ijnpc.v1i2.1149 
 
  
61 
 
THE EFFECT OF CARBOPLATIN CHEMOTHERAPY REGULATION 
ON HEARING FUNCTIONS IN PATIENTS OF NASOPHARYNGEAL 
CARCINOMA 
Ita Wahyuni1*, Denny S Utama1, Abla Ghanie1  
1ENT Department Dr. Mohammad Hoesin Palembang, Faculty of Medicine, Sriwijaya University  
 
Abstract Article Info 
Introduction: The incidence of hearing loss after treatment with carboplatin-based chemotherapy in 
nasopharyngeal carcinoma (NPC) patients were evaluated, and relationships of loss with host factors, treatment-
related factors were investigated.  
Objective: To evaluate the effect of giving a carboplatin chemotherapy regimen for 6 times chemotherapy                              
(serial chemotherapy) on hearing function in patients with nasopharyngeal carcinoma. The incidence of hearing 
loss after treatment with carboplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients were 
evaluated, and relationships of loss with host factors, treatment-related factors were investigated. 
Method: Thirty NPC patients were treated with carboplatin chemotherapy from 2015 to 2017 were analyzed. 
Pure tone audiometry and Distortion Product of Otoacoustic emission (DPOAE) were performed during the 
follow-up period, with a median time of 36 months, ranging from 24 to 36 months. Correlation of SNHL at 
frequencies (pure tone average, 0.5-8 kHz) with a series of factors was analyzed. 
Results: Among 30 participant (60 ears), using the Wilcoxon test, the mean threshold after series III was significant 
(p=0,000) and the mean of after series VI and significant (p= 0,000). The relationship between DPOAE results and pure 
tone audiometry was also carried out in the early stages of series III. Kaplan Meier's survival analysis improvement 
from post-III series (6 weeks) of participants who survived as many as 23 participants (76.67%) and in the post-
chemotherapy evaluation of VI series (15 weeks) participants who survived as many as 8 participants. Bivariate 
statistical analysis using the Spearman non-parametric correlation test, there was a significant relationship between the 
mean dose and the decrease in the hearing threshold. p=0.00 (<0.01).  
Conclusion: For NPC patients treated with carboplatin chemotherapy, There was an effect on the hearing 
function of the administration of carboplatin chemotherapy regimen for 6 series chemotherapy in patients with 
nasopharyngeal carcinoma. 
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1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) has been considered as one of the theater 
neoplasms globally. It is relatively frequent in some regions, including parts of 
South-Eastern Asia and a number of provinces in South-Eastern China From 
various reports mentioned that the malignancy in the neck head area is still a 
major health problem in the world, with an estimated 500,000 new cases each 
year. Among the various malignancies in the head area of the neck most often 
found in Indonesia are nasopharyngeal carcinoma with an incidence of around 
4.7-30 cases per 100,000 inhabitants [1-5]. 
Platinum-based chemotherapy consisting of cisplatin, carboplatin, and 
oxaliplatin, satraplatin, and transplatin have been used extensively in clinics 
since thirty years ago in the treatment of malignant head-neck tumors so that 
the side effects of using chemotherapy agents also need serious attention, 
one of them being ototoxic. Ototoxicity of platinum group chemotherapy 
drugs tends to cause sensorineural hearing loss that persists at high 
frequencies. Sensorineural deficits will increase as the drug dose 
accumulates. Carboplatin is the second generation platinum-based with 
nephrotoxic effects and ototoxic cochlear which tend to be lower than 
cisplatin. In various studies, it was found that the incidence of cisplatin 
ototoxicity was high enough that it had begun to be abandoned. However, 
the use of high doses of carboplatin or long-term accumulations of 
accumulation can occur in the inner ear ototoxicity. The pathogenesis of 
carboplatin ototoxicity is similar to that of cisplatin. Like cisplatin, 
carboplatin causes damage to Corti's organs. However, the target of damage 
caused by carboplatin in the initial phase is thought to begin from the hair 
cells continuing to the outer hair cells while the target damage caused by 
cisplatin begins in the outer hair cells. Outer hair cell damage has been 
observed in the use of high-dose carboplatin and long-term use [3-7]. 
Carboplatin is a second generation analog platinum that has been used 
extensively in chemotherapy. The chemical formula structure is diamine 
[1,1-cyclobutanedicarboxylato (2 -) - O, O '], (SP-4-2). Carboplatin is a 
second generation platinum analog of cisplatin consisting of central 
platinum atoms in the same plane as two groups of ammonia and chloride 
or 1,1-cyclobutanedicarboxylate with a ligand in the cis position. 
Carboplatin is considered to have a nephrotoxic and ototoxic effect at 
relatively lower therapeutic doses than cisplatin so that it is more widely 
used today as a platinum substitute for cisplatin. Ligands found in the form 
of carboplatin ring structures tend to be stable compared to the two chloride 
arms found in the cisplatin structure. This difference causes the molecular 
stability of carboplatin with a decrease in the toxic effects of the drug, 
including ototoxicity. The exact mechanism of carboplatin cytotoxicity is 
not clearly known. Carboplatin, like cisplatin, can induce DNA chains, 
although it requires 10 times higher drug concentrations and 7.5 times 
longer than cisplatin. Carboplatin becomes hydrolyzed, similar to cisplatin 
but a hundred times slower [8-13]. 
Large doses of carboplatin are often used to improve the antitumor 
response. Ototoxicity of carboplatin is expressed as damage to hair cells in 
the cochlea. Carboplatin in the form of crystalline powder with the 
molecular formula C6H12N2O4Pt and molecular weight around 371.25. 
Carboplatin is mixed with a water solvent of about 14 mg/mL, with Ph of 
1% solution around 5-7. Generally, carboplatin dissolves in ethanol, 
acetone, and dimethylacetamide. Carboplatin is chemically less active than 
cisplatin; its toxic effects are considered lower in the ears, kidneys, and 
central nervous system. Thus the reactivity is lower in concentrations that 
are quite large compared to the cisplatin needed to fight malignant tumors; 
thus the dose needed will be even greater. It is estimated that the dose needed 
is around 8-45 times compared to cisplatin [14-19]. 
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Carboplatin is also known to damage the kidneys (nephrotoxic) and the 
inner ear (ototoxicity). 30-32 Long-term exposure of alkaline agents can cause 
10 to 15 times increased resistance. Research shows a response by causing the 
synthesis of glutathione and metallothionein. Metallothionein is a protein that 
binds heavy metals and achieves increased levels of metals in the blood [19-22]. 
Carboplatin, as well as predominant cisplatin, affects the DNA chain 
path compared to its DNA protein. This effect is not specific to the cell cycle. 
Activation of carboplatin tends to be slower because its solubility is longer 
than cisplatin although its mechanism of action is similar to that of double 
chain DNA, causing similar biological lesions, the difference being in the 
potentiation of lower carboplatin due to differences in solubility. In patients 
with a creatinine clearance of about 60 mL/minute or more, plasma levels 
of carboplatin in a biphasic method occur after 30 minutes with intravenous 
infusion of 300 mg/m2 to 500 mg/m2 carboplatin [23-28]. 
The half-life of plasma (alpha) is 1.1 to 2 hours (n=6), and the half-life 
after the distribution period (beta) is 2.6 to 5.9 hours (n=6). Total body 
clearance, close to distribution volume and the average time is 4.4 L / hour, 
16 L and 3.5 hours. The Cmax values and areas below plasma concentrations 
of the time curves from 0 to infinity (AUC) increase linearly according to 
the dose, although the increase tends to exceed proportional doses. 
Carboplatin thus inhibits linear pharmacokinetics when it exceeds the 
studied dose range (300 mg/m2–500 mg/m2) [19, 20]. 
Studies in several experiments on animals have shown that the 
therapeutic dose of carboplatin can selectively cause damage to hair cells in 
the cochlea and type I ganglion neurons without damaging the cochlear 
outer hair cells. Selective damage from hair cells in the cochlea does not 
cause a potential cochlear microphone effect and DPOAE However, 
carboplatin in high doses or long-term accumulated doses can damage the 
inner hair cells as well as the outer cochlear hair cells causing a decrease in 
the amplitude of the cochlear microphonics in DPOAE [29-34]. 
Carboplatin does not bind to plasma proteins. There is no significant 
free protein, as is the presence of other platinum groups in the plasma. 
However, platinum from carboplatin to irreversible is bound to plasma 
proteins and eliminated slowly with a half-life of at least 5 days. The major 
pathway for eliminating carboplatin is renal excretion [1-5, 22-24]. 
Patients with creatinine clearance close to 60 mL/minute or excretion of 65% 
of the urine dose in 12 hours and 71% of the dose within 24 hours. All platinum in 
the urine 24 hours out as carboplatin. The remaining only about 3% to 5% is given 
platinum and then excreted in urine between 24 and 96 hours. There are no data yet 
to explain whether biliary excretion also occurs. In patients with creatinine clearance 
below 60 mL/minute with total body clearance and renal clearance of carboplatin 
decreases with decreasing creatinine clearance [30, 31]. 
Carboplatin as a single dose of therapy (injection of carboplatin fluid) should 
be given at a dose of 360 mg /m2 IV over 15-60 minutes at 1 day every 4 weeks. 
The intermittent dose of carboplatin should not be repeated until a minimum 
neutrophil count of 2,000 and 100,000 platelets. Patients with creatinine 
clearance below 60 mL/minute risk bone-marrow suppression including severe 
leukopenia, neutropenia, and thrombocytopenia [34-36]. 
2. MATERIAL AND METHODS 
Based on the medical record in RSUP. Dr. Moh. Hoesin Palembang in 
2015 to 2017, it found a total number of patients undergoing chemotherapy 
270 patients with head and neck regional carcinoma who were treated in the 
Department of Surgery, Department of Internal Medicine, Department of 
Children and ENT-KL Department. Of the 270 patients who underwent 
chemotherapy, as many as 129 patients used the carboplatin chemotherapy 
regimen. Data obtained from the Oncology Subdivision of the ENT-KL 
Department of RSUP. Dr. Moh Hoesin Palembang from 2015 to 2017 found 
129 patients with Nasopharyngeal carcinoma undergoing chemotherapy 
with a carboplatin regimen. This study used a prospective observational 
method to determine ototoxic events in the form of decreased hearing 
function in patients with nasopharyngeal carcinoma who underwent 
chemotherapy with carboplatin in 6 series (1 cycle) chemotherapy. This 
research has been carried out from June 2015 until February 2017. The 
number of samples that met the acceptance criteria and participated in this 
study were 30 participants from 25 minimum participants needed.  
3. RESULT 
3.1 Characteristics of decreasing hearing functions based on 
evaluation of pure tone audiometry.  
The study was done in 30 participants with the number (n) of each ear 
obtained in a total of 60 years. Characteristics based on type and degree of 
hearing loss in preliminary pure-tone audiometry screening performed before 
chemotherapy, obtained ears with normal hearing of 36 ears (60%), mild 
conductive hearing loss as much as 8 ears (13.3%), moderate conductive hearing 
loss as much as 12 ears (20%), heavy conductive hearing loss as much as 2 ears 
(3.33%), mild sensorineural hearing loss of 1 ear (1.7%), moderate sensorineural 
hearing loss of 1 ear (1.7%).  
In the post III series chemotherapy evaluation it was found that 27 ears (45%) 
with normal hearing, 5 ear mild conductive hearing (8.30%), 7 (11.67%) moderate 
conductive hearing, and 2 conductive hearing loss (3.30%). Sensorineural hearing 
loss has increased in number with 6 (10%) ears with mild sensorineural hearing loss 
and 5 (8.30%) ears with moderate sensorineural hearing loss. Conductive-
sensorineural hearing loss obtained mild hearing loss of 4 (6.67%) ears and 
moderate mixed hearing loss as much as 4 (6.67%) ears. Audiometry evaluation 
after series VI chemotherapy found normal ears (16.67%) of ears, mild conductive 
hearing loss of 4 (6.67%) ears, moderate conductive hearing loss of 6 (10%) ears. 
Mild sensorineural hearing loss was obtained in 10 (16.67%) ears; the moderate 
sensorineural hearing loss was obtained 9 (15%) ears, severe sensorineural hearing 
loss was 3 (5%) ears. Mild hearing loss is obtained in 9 (15%) ears, and moderate 
hearing loss is 6 (10%) ears. 
Based on the results of pure tone pre-chemotherapy audiometry evaluation, 
post series III chemotherapy and post-series VI chemotherapy, the mean changes in 
bone delivery threshold and airborne threshold, i.e. mean bone threshold (table 2), 
were found at 19.0833+11.585 after post-chemotherapy series the mean hearing 
threshold of bone is 21.7917+11.988. The conductive bone hearing in the post VI 
chemotherapy series showed a significant increase to 29.4375+13.271. 
 
Graphic 1 Changes in Threshold of Air Channel and Bone Conduction 
based on Pure Tone Audiometry Results (n=60) 
Analysis of changes in mean bone conduction threshold and air conduction 
was carried out by the Wilcoxon test (table 1), where a significant change in bone 
delivery threshold after series III (p=0.000) and mean change in bone delivery 
threshold after series VI was also significant (p=0.000). The mean change in air 
conductivity threshold after series III is significant (p=0.000) and the mean change 
in air conductivity threshold after series VI is also significant (p=0.000). 
 
Table 1. Wilcoxon Test for Changes in the Average of Hearing Threshold of 
Air Delivery and Bone Delivery (n=60) 
 
 
Bone 
Conduction 
Threshold 
Mean + SD 
Z p 
Air 
Conduction 
Treshold 
Mean + SD 
Z p 
Pre-Kemo 19.08+11.54   35.41+17.63   
  -4.096 0.000  -3.944 0.000 
Pasca Seri III 21.79+11.98   39.97+15.72   
  -5.576 0.000  -4.891 0.000 
Pasca Seri VI 29.43+13.27   47.30+14.73   
Wilcoxon test is significant if p <0.005 
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In this study, the degree of ototoxicity was assessed by two criteria, namely 
the National Cancer Institute's NCI-CTCAE criteria—the Common 
Terminology Criteria for Adverse Events and the criteria for ASHA (1994). Both 
of these criteria are still widely used and are standard criteria in monitoring the 
ototoxic events of chemotherapy drugs and other drugs. The NCI-CTCAE 
Criteria (National Cancer Institute-Ototoxicity Grade Common Criteria for 
Adverse Events (NCI-CTCAE) in post III series chemotherapy evaluation, of the 
30 participants studied (n=30) were considered more sensitive in detecting 
ototoxicity in the initial phase is divided into degrees I, II, and III ototoxic. 
Ototoxic grade I generally without complaint than usually decreases only occur 
unilaterally on two consecutive frequencies at high frequencies. Participants 
generally can still communicate well at the frequency of conversation but still an 
emotion. They are ototoxic degree II (26.67%) and grade III (6.67%). 
Participants generally began to complain of hearing loss (table 2). 
The ASHA criteria (1994) are assessed bilaterally in both ears so that 
the initial and unilateral phases are usually not detected. However, many 
researchers conclude that this criterion is the most ideal for declaring an 
ototoxic diagnosis that occurs bilaterally. In this study, ototoxicity in post-
series III occurred as much as 10%, and post-series VI occurred in 33.30%. 
 
Table 2. Degrees of autotoxicity based on NCI-CTCAE Criteria (n=30) 
 
Grading Ototoxicity 
Chemo III Chemo VI 
n % n % 
Normal  23 76.67% 8 26.67% 
Grade I 5 16.67% 12 40% 
Grade II 2 6.67% 8 26.67% 
Grade III 0 0.00% 2 6.67% 
 
Table 3. Degrees of ototoxicity based on ASHA Criteria (n=30) 
 
Ototoxicity Degree 
After Chemotherapy series III After Chemotherapy series VI 
n % n % 
Normal 27 90.00% 20 66.67% 
Ototoxicity 3 10.00% 10 33.30% 
 
Table 4. Conformity Test of NCI-CTCAE Autotoxicity Criteria with ASHA 
Criteria (n=30) 
 
 
NCI series III NCI seri VI 
Normal Ototoxic Normal Ototoxic 
ASHA series III     
Normal 1 0   
Ototoxicity 0 1   
ASHA seri VI     
Normal   0 1 
Ototoxicity   1 0 
Kappa 1.00  -1.00  
Std Error 0.000  0.000  
3.2 Characteristics of decreasing hearing functions based on DPOAE 
evaluation 
Tympanometry screening pre-chemotherapy was performed on 60 ear samples, 
and the results of type A tympanogram were 36 (60%) ears, As-type tympanogram as 
much as 2 (3.33%) ears, type B tympanogram 18 (30%) ears and type C tympanogram 
as many as 4 (6.60%) ears. Then 38 ear types A and As samples were monitored with 
DPOAE in post III and VI series. In post series III evaluation of 38 samples, there were 
32 (53.3%) type A tympanogram results and As (a type of As-type tympanogram) 6 
(10%) ears. In the post VI series evaluation, the results of type A tympanogram were 
28 (46.67%) ears and As type as many as 10 (16.67%) ears. 
Ototoxicity can also be analyzed at each DPOAE frequency in post series 
III evaluations and post VI series. Evaluation of DPOAE post series III at a 
frequency of 988 Hz as many as 10 ears (73.7%) with a decrease in the threshold 
of DPOAE threshold from baseline >4 dB indicating the possibility of an ototoxic 
state. At the DPOAE frequency of 1482 Hz, participants with a decrease in the 
DPOAE threshold from baseline >4 dB occurred in 8 ears. Evaluation at the 
frequency of 2222 Hz the difference in the decrease in the DPOAE threshold 
from baseline >4 dB occurred at 10 ears, and at a frequency of 2963 Hz the 
difference in the decrease in the DPOAE threshold from baseline >4 dB occurred 
in 16 ears. Evaluation at the frequency of 4444 Hz the difference in the decrease 
in the threshold of DPOAE from baseline >4 dB occurred at 17 ears, at a 
frequency of 5714 Hz the difference in the decrease in the threshold of DPOAE 
from baseline >4 dB occurred in 20 ears.  
Evaluation of DPOAE at a frequency of 8000 Hz found that the 
difference in the decrease in the DPOAE threshold from baseline >4 dB 
occurred in 23 ears. In this study also carried out ototoxicity assessment at 
each frequency by calculating the difference in DPOAE values from the 
baseline pre-chemotherapy threshold with DPOAE series III and VI 
threshold values ranging from frequency 988 Hz to a frequency of 8000 Hz. 
Ototoxicity is expressed if there is a decrease in the threshold of >4 dB from 
the baseline. In this study (table 4) can be described the percentage of the 
most ears after series III which experienced a decrease in threshold >4 dB 
from baseline values ranging from 2963 Hz at 42.1%, frequency 4444 Hz at 
17%, frequency 5714Hz at 20% and frequency 8000 Hz of 60.5%.  
DPOAE evaluation after series VI chemotherapy was also analyzed at 
a frequency of 988 Hz, the difference in decrease in DPOAE threshold from 
baseline >4 dB occurred at 18 ears, at a frequency of 1482 Hz the difference 
in DPOAE threshold from baseline >4 dB occurred at 15 ears, and at a 
frequency of 1482 Hz occurs in 12 ears, at a frequency of 2222 Hz occurs 
in 12 ears. Evaluation of the frequency of 2953 Hz found that the difference 
in decreasing the DPOAE threshold from baseline >4 dB occurred at 25 ears, 
at a frequency of 4444 Hz occurring at 28 ears, evaluation at a frequency of 
5714 Hz occurred at 29 ears and at 8000 Hz participants with a decrease in 
DPOAE threshold from baseline >4 dB occurs in 23 ears. The relationship 
between DPOAE results and pure tone audiometry was also analyzed for 38 
ear samples (table 5) carried out in post series III evaluation with a 
sensitivity value of 0.50 (50%), a specificity value of 0.56 (56%), a positive 
predictive value of 0.18 and a value negative prediction of 0.86. 
 
Table 5. Accuracy of DPOAE Evaluation Results with Series III 
Audiometry (n=38) 
 
DPOAE 3 
AUDIOMETRY 3 
P 
Ototoxic Normal Total 
Ototoxic 3 14 17 0.778* 
1.00** Normal 3 18 21 
Total 6 32 38 0.778*** 
*Pearson Chi-square 
**Continuity Correction 
***Likelihood Ratio 
 
In the post VI series evaluation (table 6) the sensitivity value was 0.64 
(64%), and specificity was 0.69 (69%), the positive predictive value was 0.74, 
and the negative predictive value was 0.58. 
 
Table 6.  Accuracy of DPOAE Evaluation Results with Series VI 
Audiometry (n=38) 
 
DPOAE 3 
AUDIOMETRY 6 
P 
Ototoxic Normal Total 
Ototoxic 14 5 19 0.049* 
0.1** Normal 8 11 19 
Total 22 16 38 0.049*** 
*Pearson Chi-square 
**Continuity Correction 
***Likelihood Ratio 
 
Based on Kaplan Meier survival analysis (graphic 2) the speed of ototoxicity 
was obtained in post-series III evaluation (6 weeks) of 23 participants with a 
survival rate of 76.67% and post-chemotherapy evaluation series VI (15 weeks), 
participants participated in 8 participants. with a percentage number of 26.67%. 
The ototoxic percentage at mid-cycle is 23.33% and at the end of the cycle 
reaches more than 50%, which is 73.33%. 
 
Graphic 2.  Kaplan Meier Analysis of the Speed of Occurrence of 
Ototoxicity Based on NCI-CTCAE Criteria (n=30) 
Based on the ASHA criteria (graphic 2) audiometry evaluation after series 
III chemotherapy found the percentage of participants who experienced ototoxic 
only 10% and participants who still did not have ototoxic or normal as much as 
90%. Evaluation after series VI found the percentage of participants who 
experienced ototoxic as much as 33.30%, and participants who were still in the 
normal category were 66.67%. 
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3.3 Analysis of bivariate of variables that are risk factors on 
decreasing hearing functions 
Based on bivariate statistical analysis using the Spearman non-
parametric correlation test, there was a significant relationship between the 
mean dose and the decrease in the hearing threshold. p=0.00 (<0.01). Kidney 
clearance (CCT) and decreased hearing threshold have a significant 
relationship p=0.00<0.01. Age of respondents with a decrease in hearing 
threshold did not have a significant relationship p=0.081 (>0.01). The mean 
dose correlation and decrease in hearing threshold is r=0.719 (>0.01), this 
indicates that there is a strong and positive relationship (not contradictory 
thus the higher the dose, the higher the risk of decreasing hearing water 
hearing threshold. Kidney and decreased hearing threshold are r=0.833 
(>0.01) this indicates that there is a relationship. 
4. DISCUSSION 
The ototoxic incidence of carboplatin increases as the increase in drug 
accumulation occurs at around 33%. Parson et al9 found that 82% of patients 
experienced significant hearing loss after high-dose carboplatin chemotherapy. 
Schweitzer (1993) calculated the incidence of cisplatin, which induces mean 
hearing loss of about 62% (range between 11% -97%). According to Kennedy et 
al. 20 (1998), the incidence of carboplatin inducing hearing loss is estimated to 
be around 19% -83%. According to Blackley et al. (1994), the risk factors that 
cause hearing loss in the use of ototoxic drugs are generally associated with 
doses, although many other factors play a role. According to Fischel-Ghidsian45, 
the possibility of ototoxicity that causes hearing loss in each is influenced by 
various biochemical processes, physiological factors, and genetic factors. In this 
study, a bivariate correlation analysis was performed using the Spearman 
nonparametric correlation test, which found a significant relationship between 
the mean dose and the decrease in the hearing threshold. p=0.005 (<0.01). There 
was a significant correlation between mean dose and kidney clearance in 
creatinine clearance (CCT), i.e. p=0.005 (<0.01). Several studies have been 
conducted on the effect of the cumulative dose of carboplatin on ototoxicity and 
obtained a cumulative dose above 400 mg/m2. Li, Womer, and Sibler (2004) in 
their study conducted a pure tone audiometry assessment of 153 children, ages 5 
to 18 years who received cisplatin therapy at therapeutic doses of 40 to 200 
mg/m2 each cycle. The risk of bilateral hearing loss at high frequencies occurs 
significantly, along with the increase in the cumulative dose of the drug 
(p<0.005). Research conducted by Brock et al. (1991) 26 retrospectively assessed 
29 children who had been treated with 60-100 mg/m2 each cycle [1-7, 20, 24]. 
The ototoxic risk increased significantly according to the cumulative dose of 
the drug (p=0.027). There has been no evidence of loss hearing in patients who 
received a therapeutic dose of <400 mg/m2 per cycle of chemotherapy. 19-21.26 
The mean dose correlation and decrease in hearing threshold were r=0.719 (>0.01) 
indicating that there was a strong relationship and the direction of a positive 
relationship (not different thus the higher the total dose, the higher the decrease in 
hearing water hearing threshold. Lakhai (2006) 56 in his study concluded that the 
risk of hearing loss due to ototoxic drugs generally depends on the dose, duration, 
frequency and method of administration of the drug [35-37]. 
Age of respondents with a decrease in hearing threshold did not have a 
significant relationship p=0.101 (>0.01). Age of the respondent and kidney 
clearance, there was no significant relationship p = 0.079. Various studies 
have found an association between age and an increase in ototoxic events 
induced by platinum group chemotherapy [22, 28, 35]. 
The incidence increases especially in children and the elderly. Li et al. (2004) 
56 examined pediatric patients with a mean age of less than 5 years who received 
carboplatin therapy. It was found that about 40% of children experience moderate 
to severe sensorineural hearing loss after receiving a cumulative dose of >400 
mg/m2. The risk of only 5% occurs in children aged 15-20 years. Helson et al. 
(1978) have also investigated the ototoxic induced platinum group chemotherapy 
drugs with a cumulative dose of  >400 mg/m2, and the incidence of sensorineural 
hearing loss was increased at the age of 46 years [7, 36-39]. 
Age correlation and decrease in hearing threshold r=-0.217 a weak 
correlation (negative) leads to a weak correlation. Correlation of age and 
kidney clearance r=-0,229 occurs weak correlation leads to negative 
(opposite). Correlation of mean doses and renal clearance: r = 0.816 (>0.01) 
this indicates that there are a very strong relationship and the direction of a 
positive relationship (not contradictory (support). The assessment of renal 
function is done by measuring creatinine clearance levels. Bokemeyer et al 
(1998) 41 examined the risk of ototoxicity in 86 patients who had complete 
remission of about 12 months [40-42]. 
Serum creatinine levels were measured after cisplatin administration and in 
patients who showed increased creatinine levels (92 µmol) experienced persistent 
sensorineural hearing loss symptoms compared with patients with lower creatinine 
levels (92 µmol) (p=0.04). Schaefer et al42 conducted a study on patients with 
impaired renal function (poor creatinine clearance) had a greater risk of ototoxic 
events as drug dosages increased. Correlation of renal clearance and decreased 
hearing threshold of water: r=0.833 (>0.01) this indicates that there is a powerful 
relationship, and the direction of a positive relationship ling supports. [43-45]. 
 
5. CONCLUSION 
 
There was an effect of the administration of carboplatin chemotherapy 
regimen for 6 series chemotherapy (1 cycle) on hearing function in patients 
with head and neck regional carcinoma in the form of a significant decrease 
in bone delivery threshold and air delivery. The incidence of loss hearing in 
the administration of carboplatin chemotherapy is influenced by the average 
dose of the drug given and the individual clearance level of creatinine. 
DPOAE can be a good alternative screening tool in monitoring the 
ototoxicity of chemotherapy drugs. 
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